ResMed and Inspire Medical Stocks Plunge After Eli Lilly’s Positive Zepbound Data; Citi Lowers Ratings
ResMed (RMD) and Inspire Medical Systems (INSP) stocks fell dramatically in early Monday trading. This sharp drop was due to Eli Lilly's positive clinical trial results for their new drug, Zepbound (tirzepatide), aimed at treating obstructive sleep apnea (OSA).
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
